(Reuters) – Amgen will test its obesity drug candidate in patients at risk of obesity-related conditions such as heart, liver and kidney diseases in its late-stage trial, the company’s CEO Robert Bradway said at a Morgan Stanley healthcare conference on Wednesday.
(Reporting by Puyaan Singh; Editing by Shreya Biswas)
Comments